Business, energy, technology, markets and global industry news from Business News Today

Alexion Pharmaceuticals

PharmaDeviceNews Alexion Pharmaceuticals
Editorial infographic illustrating Affinia Therapeutics’ AFTX-201 BAG3 heart gene therapy programme, featuring an anatomical heart, DNA strands and clinical research imagery, with highlights on the 22-patient trial, promising animal results and unproven human safety and efficacy.
Pharma & Biotech

Affinia presents AFTX-201 preclinical data and UPBEAT trial design at HFSA 2026

Affinia advances AFTX-201 into a 22-patient BAG3 heart gene therapy trial after promising animal results. Human safety and efficacy remain unproven.

Read More
A clinician reviews bone imaging with a patient as Soft Bones urges South Korea to widen hypophosphatasia treatment access and reconsider reimbursement rules that can restrict therapy for late-diagnosed adults with pediatric-onset HPP. Representative image.
Pharma & Biotech

South Korea recognizes HPP as a lifelong rare disease, so why must covered treatment start before age 19?

Soft Bones urges South Korea to widen HPP reimbursement as age and radiographic criteria restrict treatment access for some patients.

Read More